Bizrolertinib vs Trastuzumab Deruxtecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Bizrolertinib
Developed by Roche
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT05593094 (registry estimate)
No aligned efficacy figure on record for this race.
Trastuzumab Deruxtecan
Marketed by Daiichi Sankyo and partners
NCT03523585 · Phase 3 · completed
The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.
Next expected readout: January 2027 · NCT06797622 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) (met)
Result source: NCT03523585
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Bizrolertinib: no structured comparison results are available for HER2-Positive Breast Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Trastuzumab Deruxtecan
show 1 more result
show 1 more result
show 2 more results
show 4 more results
Available safety results
Trastuzumab Deruxtecan
| Dropout rate | 76.8% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results62.5%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 70%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 88.9%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 33.3%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 71.4%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 18.2% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results—Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence —Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 25.5% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more results0%Cohort 1 NCT04420598 · Phase 2 · registry result, not featured evidence 10%Cohort 2 NCT04420598 · Phase 2 · registry result, not featured evidence 55.6%Cohort 3 NCT04420598 · Phase 2 · registry result, not featured evidence 16.7%Cohort 4 NCT04420598 · Phase 2 · registry result, not featured evidence 57.1%Cohort 5 NCT04420598 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | nausea 72.3% alopecia 37.1% vomiting 37.1% NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 5 more resultsfatigue 75% constipation 62.5% nausea 50% NCT04420598 · Phase 2 · registry result, not featured evidence fatigue 90% nausea 70% aspartate aminotransferase increased 50% NCT04420598 · Phase 2 · registry result, not featured evidence anaemia 44.4% fatigue 44.4% neutropenia 44.4% NCT04420598 · Phase 2 · registry result, not featured evidence nausea 57.1% anaemia 42.9% fatigue 42.9% NCT04420598 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bizrolertinib's landscape · Trastuzumab Deruxtecan's landscape